Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP824490.RAldQ_2bV1vEuby162f4b42f_Vwtb5dwlZSnwBz6RQU_Y130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP824490.RAldQ_2bV1vEuby162f4b42f_Vwtb5dwlZSnwBz6RQU_Y130_assertion type Assertion NP824490.RAldQ_2bV1vEuby162f4b42f_Vwtb5dwlZSnwBz6RQU_Y130_head.
- NP824490.RAldQ_2bV1vEuby162f4b42f_Vwtb5dwlZSnwBz6RQU_Y130_assertion description "[Since the Bayer preparation is no longer available for treatment of large series of patients with ALL, the present study was designed to prospectively evaluate coagulation and fibrinolytic changes in leukaemic children receiving different doses of Medac ASP, which is now available for treatment of childhood ALL.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP824490.RAldQ_2bV1vEuby162f4b42f_Vwtb5dwlZSnwBz6RQU_Y130_provenance.
- NP824490.RAldQ_2bV1vEuby162f4b42f_Vwtb5dwlZSnwBz6RQU_Y130_assertion evidence source_evidence_literature NP824490.RAldQ_2bV1vEuby162f4b42f_Vwtb5dwlZSnwBz6RQU_Y130_provenance.
- NP824490.RAldQ_2bV1vEuby162f4b42f_Vwtb5dwlZSnwBz6RQU_Y130_assertion SIO_000772 8857948 NP824490.RAldQ_2bV1vEuby162f4b42f_Vwtb5dwlZSnwBz6RQU_Y130_provenance.
- NP824490.RAldQ_2bV1vEuby162f4b42f_Vwtb5dwlZSnwBz6RQU_Y130_assertion wasDerivedFrom befree-20150227 NP824490.RAldQ_2bV1vEuby162f4b42f_Vwtb5dwlZSnwBz6RQU_Y130_provenance.
- NP824490.RAldQ_2bV1vEuby162f4b42f_Vwtb5dwlZSnwBz6RQU_Y130_assertion wasGeneratedBy ECO_0000203 NP824490.RAldQ_2bV1vEuby162f4b42f_Vwtb5dwlZSnwBz6RQU_Y130_provenance.